These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 23083688)

  • 1. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
    Stanford RH; Blanchette CM; Roberts MH; Petersen H; Fuhlbrigge AL
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):343-51. PubMed ID: 23083688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Delea TE; Hagiwara M; Stanford RH; Stempel DA
    Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powder.
    Hagiwara M; Delea TE; Stanford RH
    J Asthma; 2013 Apr; 50(3):287-95. PubMed ID: 23305687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
    Blanchette CM; Culler SD; Ershoff D; Gutierrez B
    Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS; Yawn BP
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
    Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
    Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
    Stoloff SW; Stempel DA; Meyer J; Stanford RH; Carranza Rosenzweig JR
    J Allergy Clin Immunol; 2004 Feb; 113(2):245-51. PubMed ID: 14767437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis.
    Tunceli O; Williams SA; Kern DM; Elhefni H; Pethick N; Wessman C; Zhou S; Trudo F
    J Allergy Clin Immunol Pract; 2014; 2(6):719-26. PubMed ID: 25439363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
    Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
    Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population.
    Simoni-Wastila L; Yang HW; Blanchette CM; Zhao L; Qian J; Dalal AA
    Curr Med Res Opin; 2009 Nov; 25(11):2729-35. PubMed ID: 19778165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma.
    Stempel DA; Riedel AA; Carranza Rosenzweig JR
    Curr Med Res Opin; 2006 Mar; 22(3):463-70. PubMed ID: 16574030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy.
    Allen-Ramey FC; Bukstein D; Luskin A; Sajjan SG; Markson LE
    J Manag Care Pharm; 2006 May; 12(4):310-21. PubMed ID: 16792437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to asthma controller medication regimens.
    Stempel DA; Stoloff SW; Carranza Rosenzweig JR; Stanford RH; Ryskina KL; Legorreta AP
    Respir Med; 2005 Oct; 99(10):1263-7. PubMed ID: 16140227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy.
    Hagiwara M; Delea TE; Stanford RH; Stempel DA
    Allergy Asthma Proc; 2010; 31(3):203-10. PubMed ID: 20534183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing outcomes in patients with persistent asthma: a registry of two therapeutic alternatives.
    O'Connor RD; Gilmore AS; Manjunath R; Stanford RH; Legorreta AP; Jhingran PM
    Curr Med Res Opin; 2006 Mar; 22(3):453-61. PubMed ID: 16574029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol.
    Blais L; Beauchesne MF; Forget A
    Respir Med; 2009 Feb; 103(2):237-43. PubMed ID: 18930647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.